- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06798012
En studie av Tak-411 hos voksne med kronisk inflammatorisk demyeliniserende polyradiculoneuropati (CIDP) (CASCA)
En fase 2, åpen etikett, proof-of-concept-studie for å undersøke effektiviteten, sikkerheten og toleransen av TAK-411 hos voksne personer med kronisk inflammatorisk demyeliniserende polyradiculoneuropathy (CASCA-studien)
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG).
TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP.
The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial.
Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose.
During the study, participants may visit their study clinic up to approximately 21 times.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Takeda Contact
- Telefonnummer: +1-877-825-3327
- E-post: medinfoUS@takeda.com
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- Rekruttering
- University of Calgary
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 403-210-7006
- E-post: chris.white@ahs.ca
-
Hovedetterforsker:
- Christopher White
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Rekruttering
- University Health Network
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 416-340-3662
- E-post: hans.katzberg@uhn.ca
-
Hovedetterforsker:
- Hans Katzberg
-
-
-
-
-
Bogotá, Colombia, 111711
- Rekruttering
- Universidad del Rosario
-
Ta kontakt med:
- Site Contact
- E-post: drandresdiazcampos@gmail.com
-
Hovedetterforsker:
- Andres Diaz Campos
-
Bucaramanga, Colombia, 680001
- Rekruttering
- Fundacion Oftalmologica de Santander - FOSCAL
-
Ta kontakt med:
- Site Contact
- Telefonnummer: (577) 6382828
- E-post: ivanmauricio@rocketmail.com
-
Hovedetterforsker:
- Ivan Peña
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 50021
- Rekruttering
- Neuro ClinicaS.A.S
-
Ta kontakt med:
- Site Contact
- Telefonnummer: (604) 3222813
- E-post: juan.solano@udea.edu.co
-
Hovedetterforsker:
- Juan Marcos Solano Atehortua
-
-
D.C.
-
Bogotá, D.C., Colombia
- Rekruttering
- Hospital Universitario San Ignacio
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 2473 57 (1) 5946161
- E-post: luciamarent@gmail.com
-
Hovedetterforsker:
- Alba Lucia Marentes Cubillos
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760032
- Rekruttering
- Fundacion Valle del Lili
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 4022 - 4028 (602) 3319090
- E-post: francisco.arias@fvl.org.co
-
Hovedetterforsker:
- Francisco Arias Mora
-
-
-
-
California
-
La Jolla, California, Forente stater, 92093
- Rekruttering
- University of California San Diego
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 619-543-3500
- E-post: dferrey@health.ucsd.edu
-
Hovedetterforsker:
- Dominic Ferrey
-
San Francisco, California, Forente stater, 94109
- Rekruttering
- California Pacific Medical Center
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 415-600-3604
- E-post: Liberty.Jenkins@sutterhealth.org
-
Hovedetterforsker:
- Liberty Jenkins
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20017
- Rekruttering
- MedStar Georgetown University Hospital
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 202-681-8127
- E-post: Noushin.Jazebi@medstar.net
-
Hovedetterforsker:
- Noushin Jazebi
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32209
- Rekruttering
- UF Health Neurology - Jacksonville
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 904-244-9922
- E-post: Michael.Pulley@jax.ufl.edu
-
Hovedetterforsker:
- Michael Pulley
-
Miami, Florida, Forente stater, 33133
- Rekruttering
- Visionary Investigators Network
-
Hovedetterforsker:
- Andrew Lerman
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 833-732-2484
- E-post: support@VINTrials.com
-
Rockledge, Florida, Forente stater, 32955
- Rekruttering
- Knight Neurology
-
Hovedetterforsker:
- Vaibhav Shah
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 855-564-4485
- E-post: vshah@knightneurology.com
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- University of South Florida
-
Hovedetterforsker:
- Kathleen Murray
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 813-974-9413
- E-post: jessshaw@usf.edu
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 404-727-1638
- E-post: christina.nicole.fournier@emory.edu
-
Hovedetterforsker:
- Christina Nicole Fournier
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
Hovedetterforsker:
- Fernanda Wajnsztajn Yungher
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 617-667-2501
- E-post: Agottli2@bidmc.harvard.edu
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 507-284-5236
- E-post: pinto.marcus@mayo.edu
-
Hovedetterforsker:
- Marcus Pinto
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65212-0001
- Rekruttering
- The Curators of the University of Missouri on behalf of University of Missouri Health Care
-
Hovedetterforsker:
- William Arnold
-
Ta kontakt med:
- Site Contact
- E-post: wdavidarnold@health.missouri.edu
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- The Washington University
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 314-273-8160
- E-post: C.roach@wustl.edu
-
Hovedetterforsker:
- Charles Roach
-
-
North Carolina
-
Raleigh, North Carolina, Forente stater, 27607
- Rekruttering
- Velocity Clinical Research - Raleigh
-
Hovedetterforsker:
- Timothy Ryan
-
Ta kontakt med:
- Site Contact
- E-post: tryan@velocityclinical.com
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Penn Blood Disorders Program - Hospital of The University of Pennsylvania
-
Hovedetterforsker:
- Chafic Karam
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 503-494-0744
- E-post: Chafic.Karam@Pennmedicine.upenn.edu
-
-
Washington
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington
-
Ta kontakt med:
- Site Contact
- Telefonnummer: 206-598-7688
- E-post: mdweiss@uw.edu
-
Hovedetterforsker:
- Michael Weiss
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria
-
The participant is at least 18 years of age, inclusive, at the time of signing the Informed Consent Form (ICF).
-
The participant has a body weight of less than or equal to (<=) 150 kilogram (kg).
-
The participant has a documented diagnosis of typical CIDP, as confirmed by a neurologist specializing/experienced in neuromuscular diseases and consistent with the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 criteria.
-
The participant has responded to IgG treatment in the past (documented partial or complete resolution of neurological symptoms and deficits).
-
The participant has had disease activation within 24 months before screening, as documented in medical records and in the opinion of the investigator, defined as one of the following:
- Clinically meaningful deterioration of symptoms on interruption or dose reduction of IgG treatment.
- Clinically meaningful deterioration of symptoms requiring IgG treatment dose increase with subsequent clinical improvement.
- Clinically meaningful deterioration of symptoms at the end of IgG treatment dose interval with improvement after next dose administration.
-
The participant is on a stable dose of immunoglobulin treatment intravenously (IGIV) treatment, (within the dose range of 0.4 to 2.4 grams per kilogram [g/kg] every 2 to 6 weeks [inclusive]). A stable dose is defined as no change greater than 10 percentage (%) in frequency or dose of IGIV therapy within the 3 months before and throughout screening.
-
The participant has an INCAT score between 0 and 7 (inclusive) at screening.
Key Exclusion Criteria
-
The participant has a documented diagnosis of a CIDP variant per EAN/PNS 2021 criteria.
-
The participant has any neuropathy of other causes, including the following:
- Hereditary demyelinating neuropathies, such as hereditary sensory and motor neuropathy, Charcot-Marie-Tooth disease, and hereditary sensory and autonomic neuropathies.
- Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and nondiabetic lumbosacral radiculoplexus neuropathy, lymphoma, amyloidosis.
- Multifocal motor neuropathy.
- Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy.
- Diabetic peripheral neuropathy.
-
The participant has any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or that may interfere with assessment of CIDP or outcome measures, including (but not limited to) multiple sclerosis, arthritis, stroke, and Parkinson's disease.
-
The participant is required to take or has taken either of the following for treatment of CIDP:
- Immunomodulatory/immunosuppressive agents (except IGIV) that include, but are not limited to, complement inhibitors, efgartigimod, and chemotherapeutic drugs, within 3 months or 5 half-lives, whichever is longer, of screening.
- B-cell affecting biologics (e.g. rituximab) within 6 months of screening.
Note: Participants on a long-term, stable dosing regimen of certain immunomodulatory agents (eg, hydroxychloroquine) for any disease other than CIDP may be eligible, provided the dose regimen has been stable for 3 months before screening and is expected to remain stable throughout the study.
-
The participant has undergone plasma exchange within 3 months of screening.
-
The participant has a history of malignancy with less than 2 years of complete remission before screening, or active malignancy requiring chemotherapy and/or radiotherapy.
Note: Participants with adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or stable prostate cancer not requiring treatment are eligible.
-
The participant has experienced deep vein thrombosis or arterial thromboembolic events (example, cerebrovascular accident, pulmonary embolism) within 12 months of screening.
-
The participant has any medical condition, laboratory finding, or physical examination finding that precludes participation or with clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the study or place the participant at undue medical risk.
-
The participant has participated in another clinical study involving an IP or investigational device within 30 days before screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TAK-411
Participants will receive TAK-411 400 milligrams per kilogram (mg/kg), IV infusion as an induction dose on Day 1 of initial treatment period. The induction dose may be repeated once after 3 weeks if participants exhibit no clinical change. Thereafter, participants will receive TAK-411 200 mg/kg, IV infusion every 3 weeks for a total of 24 weeks (initial treatment period), followed by an optional additional 27 weeks (extended treatment period). |
TAK-411 IV infusion.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Improvement in Functional Ability at Week 24
Tidsramme: At Week 24
|
Improvement in functional ability is defined as decrease of >=1 point in INCAT score at Week 24 compared with baseline (last assessment before first investigational product [IP] administration on Day 1). INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. |
At Week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall deltakere med bivirkninger av behandlingsopplevelse (TEAES)
Tidsramme: Fra Start of Study Drug Administration opp til 54 uker
|
Fra Start of Study Drug Administration opp til 54 uker
|
|
|
Antall deltakere med avvikling av infusjon
Tidsramme: Fra Start of Study Drug Administration opp til 54 uker
|
Fra Start of Study Drug Administration opp til 54 uker
|
|
|
Antall deltakere med antistoffer mot vertscelleproteiner (HCP), Beta-1,4-galaktosyltransferase (B4Galt1) og alfa-2,6-Sialyltransferase (ST6GAL1)
Tidsramme: Opptil 54 uker
|
Opptil 54 uker
|
|
|
Number of Participants With Improvement in Functional Ability at Weeks 12 and 54
Tidsramme: At 12 and 54 weeks
|
Improvement in functional ability is defined as decrease of >=1 point in the adjusted INCAT score at 12 and 54 weeks compared with baseline (last assessment before first IP administration on Day 1). INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. |
At 12 and 54 weeks
|
|
Change From Baseline in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Score
Tidsramme: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. |
Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
|
Change From Screening in the Adjusted INCAT Score
Tidsramme: Screening, at 12, 24 and 54 weeks
|
INCAT disability scale consists of upper and lower extremity components, which are scored based on a participant's level of impairment/disability in their arms and legs, respectively. Each component is scored from 0 to 5 points, which are summed for an overall INCAT disability score ranging from 0 to 10 points, where a score of 0 indicates no signs of disability (example, no upper limb problems and walking not affected) and a score of 10 indicates most severe disability (example, inability to move either arm for any purposeful movement and restricted to a wheelchair, unable to stand and walk a few steps with help). Adjusted INCAT disability score remains identical to INCAT disability score, except that changes in upper limb function from 0 (normal) to 1 (minor symptoms) are excluded. |
Screening, at 12, 24 and 54 weeks
|
|
Number of Participants With Improvement in Functional Ability on Inflammatory Rasch-built Overall Disability Scale (I-RODS) Score
Tidsramme: At 12, 24 and 54 weeks
|
Improvement in functional ability defined as increase of greater than or equal to (>=) 4 points in the raw summed I-RODS score at 12, 24, and 54 weeks compared with baseline. I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows:0 (impossible to perform),1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes. |
At 12, 24 and 54 weeks
|
|
Change From Baseline in I-RODS Score
Tidsramme: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
The I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. The I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows: 0 (impossible to perform), 1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes. |
Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
|
Change From Screening in I-RODS Score
Tidsramme: Screening, at 12, 24 and 54 weeks
|
The I-RODS is a validated, participants-reported, linearly weighted overall disability scale that was specifically designed to capture current activity and social participation limitations in participants with immune-mediated peripheral neuropathies including CIDP. The I-RODS comprises 24 items for which participants are asked to rate their functioning related to a variety of everyday tasks at the moment of completion. The participant assigns a score between 0 and 2 to each item as follows: 0 (impossible to perform), 1 (performed with difficulty), 2 (easily performed) with a lower score indicating more severe activity and social participation limitations. A total I-RODS score of 0 (complete disability) to 48 (no disability) is tabulated by totalling the 24-item responses where higher score represents better outcomes. |
Screening, at 12, 24 and 54 weeks
|
|
Change From Baseline in Medical Research Council Sum Score (MRC-SS)
Tidsramme: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
The MRC-SS is used clinician-reported measure of muscle strength. Assessments are conducted bilaterally on six muscle groups: upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and foot dorsal flexors. Each muscle is rated from 0 to 5, where 0 indicates no visible contraction and 5 indicates normal strength. The scores are summed to obtain the MRC-SS, which ranges from 0 (quadriplegic) to 60 (normal strength). |
Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
|
Change From Screening in MRC-SS
Tidsramme: Screening, at 12, 24 and 54 weeks
|
The MRC-SS is used clinician-reported measure of muscle strength. Assessments are conducted bilaterally on six muscle groups: upper arm abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and foot dorsal flexors. Each muscle is rated from 0 to 5, where 0 indicates no visible contraction and 5 indicates normal strength. The scores are summed to obtain the MRC-SS, which ranges from 0 (quadriplegic) to 60 (normal strength). |
Screening, at 12, 24 and 54 weeks
|
|
Change From Baseline in Bilateral Hand Grip Strength
Tidsramme: Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
Bilateral hand grip strength assessments will be performed by prescribing physicians or qualified designees using the Martin Vigorimeter, measuring strength in kilopascals (kPa) ranging from 0 to 160 kPa. |
Baseline (last assessment prior first dose on Day 1), at 12, 24 and 54 weeks
|
|
Change From Screening in Bilateral Grip Strength
Tidsramme: Screening, at 12, 24 and 54 weeks
|
Bilateral hand grip strength assessments will be performed by prescribing physicians or qualified designees using the Martin Vigorimeter, measuring strength in kPa ranging from 0 to 160 kPa. |
Screening, at 12, 24 and 54 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Study Director, Takeda
Publikasjoner og nyttige lenker
Hjelpsomme linker
- <p>Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language.</p>
- <p>Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.</p>
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i nervesystemet
- Patologiske prosesser
- Nevromuskulære sykdommer
- Kronisk sykdom
- Sykdomsattributter
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Sykdommer i det perifere nervesystemet
- Autoimmune sykdommer i nervesystemet
- Demyeliniserende sykdommer
- Polynevropatier
- Polyradikulonevropati
- Patologiske tilstander, tegn og symptomer
- Polyradiculonevropati, kronisk inflammatorisk demyeliniserende
Andre studie-ID-numre
- TAK-411-2001
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Tilgangskriterier for IPD-deling
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .